Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller combo under study: could it improve chronic pain treatment?

NCT ID NCT07710560

Not yet recruiting Disease control Sponsor: Hunan Kelun Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial investigates how a new experimental drug called KL0011034 interacts with alfentanil, a strong opioid painkiller, in adults with moderate-to-severe chronic pain. The study measures how the drugs affect each other's levels in the body and monitors safety. Participants receive single doses of each drug alone and together to compare the effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KL0011034 injection and alfentanil hydrochloride injection
What this could lead to
If successful, this study could help determine safe dosing when combining KL0011034 with alfentanil for chronic pain management.
What could go wrong
This is an early-phase trial with only 27 participants, so results may not apply broadly. Drug interactions could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC PAIN

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Third XIANGYA Hospital of Central South University

    Changsha, Hunan, 410205, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.